FULGENT GENETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.1 USD | +0.35% |
|
-1.28% | -30.47% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 270.9 | 1,265 | 3,001 | 900.1 | 856.7 | 601 | - | - |
| Enterprise Value (EV) 1 | 258.9 | 980.3 | 3,001 | 379.5 | 433.7 | -199 | -153.8 | -109.1 |
| P/E ratio | -645 x | 5.85 x | 6.14 x | 6.43 x | -5.13 x | -8.7 x | -10.7 x | -11.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.33 x | 3 x | 3.02 x | 1.45 x | 2.96 x | 2.15 x | 1.87 x | 1.71 x |
| EV / Revenue | 7.96 x | 2.32 x | 3.02 x | 0.61 x | 1.5 x | -0.71 x | -0.48 x | -0.31 x |
| EV / EBITDA | 53.3 x | 3.25 x | 4.27 x | 1.48 x | 288 x | 7.67 x | 14.9 x | -53.7 x |
| EV / FCF | 61,675,894 x | 9,415,324 x | - | 1,616,672 x | - | - | - | - |
| FCF Yield | 0% | 0% | - | 0% | - | - | - | - |
| Price to Book | 3.36 x | 2.58 x | - | 0.69 x | 0.76 x | 0.55 x | 0.56 x | 0.58 x |
| Nbr of stocks (in thousands) | 20,998 | 24,274 | 29,831 | 30,225 | 29,633 | 29,901 | - | - |
| Reference price 2 | 12.90 | 52.10 | 100.6 | 29.78 | 28.91 | 20.10 | 20.10 | 20.10 |
| Announcement Date | 3/10/20 | 3/4/21 | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.53 | 421.7 | 992.6 | 619 | 289.2 | 279.4 | 321.5 | 350.8 |
| EBITDA 1 | 4.854 | 301.3 | 703.6 | 257.1 | 1.504 | -25.95 | -10.3 | 2.03 |
| EBIT 1 | -0.428 | 290.2 | 676 | 178.5 | -195.5 | -83.85 | -74.01 | -64.15 |
| Operating Margin | -1.32% | 68.8% | 68.1% | 28.84% | -67.61% | -30.02% | -23.02% | -18.29% |
| Earnings before Tax (EBT) 1 | 0.409 | 291.7 | 677.3 | 184 | -174.1 | -86.94 | -74.66 | -81 |
| Net income 1 | -0.411 | 214.3 | 507.4 | 143.4 | -167.8 | -69.35 | -58.5 | -57 |
| Net margin | -1.26% | 50.82% | 51.12% | 23.17% | -58.03% | -24.82% | -18.19% | -16.25% |
| EPS 2 | -0.0200 | 8.910 | 16.38 | 4.630 | -5.630 | -2.310 | -1.885 | -1.730 |
| Free Cash Flow | 4.198 | 104.1 | - | 234.7 | - | - | - | - |
| FCF margin | 12.91% | 24.69% | - | 37.93% | - | - | - | - |
| FCF Conversion (EBITDA) | 86.49% | 34.56% | - | 91.3% | - | - | - | - |
| FCF Conversion (Net income) | - | 48.58% | - | 163.7% | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/4/21 | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 227.9 | 251.7 | 320.3 | 125.3 | 105.7 | 67.7 | 66.17 | 67.85 | 84.69 | 70.5 | 65.36 | 69.06 | 71.06 | 73.91 | 75.88 |
| EBITDA 1 | 167.3 | 159.8 | 213.4 | 31.05 | 10.17 | -15.08 | -7.168 | -2.707 | 18.14 | -6.759 | -9.241 | -6.778 | -3.711 | -6.219 | -5.676 |
| EBIT 1 | 160.1 | 150.8 | 201.9 | 12.79 | 0.352 | -36.55 | -24.82 | -19.8 | 0.214 | -151.1 | -22.31 | -20.94 | -19.32 | -20.95 | -20.44 |
| Operating Margin | 70.25% | 59.93% | 63.05% | 10.21% | 0.33% | -53.99% | -37.52% | -29.18% | 0.25% | -214.34% | -34.13% | -30.33% | -27.19% | -28.34% | -26.94% |
| Earnings before Tax (EBT) 1 | 159.8 | 150.8 | 202 | 13.75 | 1.757 | -33.46 | -21.05 | -14.7 | 6.86 | -145.2 | -22.89 | -21.55 | -19.64 | -22.36 | -20.61 |
| Net income 1 | 122.5 | 104.3 | 154 | 11.54 | 1.719 | -23.83 | -15.34 | -11.23 | -13.11 | -128.1 | -18.2 | -17.39 | -16.03 | -17.73 | -16.1 |
| Net margin | 53.77% | 41.46% | 48.08% | 9.2% | 1.63% | -35.2% | -23.18% | -16.55% | -15.48% | -181.76% | -27.85% | -25.18% | -22.55% | -23.99% | -21.21% |
| EPS 2 | 3.930 | 3.340 | 4.930 | - | 0.0600 | -0.8000 | -0.5200 | -0.3800 | -0.4400 | -4.300 | -0.6150 | -0.5750 | -0.5250 | -0.5850 | -0.5300 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/23/22 | 5/3/22 | 8/4/22 | 11/7/22 | 2/28/23 | 5/5/23 | 8/4/23 | 11/3/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 12 | 284 | - | 521 | 423 | 800 | 755 | 710 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 4.2 | 104 | - | 235 | - | - | - | - |
| ROE (net income / shareholders' equity) | 5.4% | 65.7% | - | 14.8% | -14% | -2.89% | -2.95% | -2.81% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 3.840 | 20.20 | - | 43.00 | 38.10 | 36.90 | 35.80 | 34.80 |
| Cash Flow per Share | - | 5.850 | - | 8.190 | - | - | - | - |
| Capex 1 | 1.32 | 36.5 | - | 18.8 | 22.2 | 25.9 | 29.8 | 34.6 |
| Capex / Sales | 4.05% | 8.66% | - | 3.03% | 7.68% | 9.27% | 9.25% | 9.88% |
| Announcement Date | 3/10/20 | 3/4/21 | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
20.1
USD
Average target price
26.67
USD
Spread / Average Target
+32.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.47% | 601M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- FLGT Stock
- Financials Fulgent Genetics, Inc.
